Dr Ong Shin Yeu

Dr Ong Shin Yeu is a Senior Consultant at the Department of Haematology at Singapore General Hospital and excels in clinical care of patients receiving immunotherapy for Lymphoma. She is also a talented researcher and clinical trialist with expertise in Lymphoma and Immunotherapy. After receiving a master’s degree in biomedical engineering from Johns Hopkins University, USA, Dr Ong received medical training from Duke-NUS Graduate Medical School, Singapore, and graduated the top of her class in Medicine with the Soo Khee Chee Award. Dr Ong has authored or co-authored more than 50 publications in prominent journals including Nature Cancer, Science & Translational Medicine, and American Journal of Hematology. She was recognized for research excellence with the Singhealth Soo Kee Chee Publish award.  Dr Ong received cell therapy training at the prestigious City of Hope Medical Center, Duarte, USA where she gained expertise in care of patients receiving commercial and trial cell therapy products. Upon her return, Dr Ong was also awarded the prestigious NMRC clinical trial grant investigating cell therapy. Over the years, Dr Ong's commitment to improve patient care and support patients through every aspect of their journey has earned multiple “Service with the heart" awards.

• ​Clinical Tutor – Yong Loo Lin School of Medicine, NUS
• Clinical Assistant Professor – Duke-NUS Medical School 
  

• ​Singapore Health Manpower Development Plan Award (2020)
• Singhealth Service with a Heart Award (2019)
• Singhealth Outstanding Resident Award (2016)
• Singhealth Service with a Heart Award (2016)
• Singhealth Seah Cheng Siang Gold Medal in Medicine, Singapore (2012)
• Duke-NUS Shaw Foundation Scholarship (2008)
  

• ​Ong SY, Lim JQ, Grigoropoulos N, Laurensia Y, Huang D, Chia BKH, et al. No association between ECSIT germline mutations and hemophagocytic  lymphohistiocytosis in natural killer/T-cell lymphoma. Vol. 106, Haematologica. 2021. p. 1737–9. 
• Lee W-HS, Ye Z, Cheung AMS, Goh YPS, Oh HLJ, Rajarethinam R, et al. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells. Mol Cancer Ther [Internet]. 2021;20(9):1702–12. 
• Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, et al. A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). Vol. 11, Blood cancer journal. 2021. p. 150. 
• Ong SY, Tan CW, Ramya V, Malik AA, Lee XH, Hwang JCC, et al. Risk factors and predictors of treatment responses and complications in immune thrombocytopenia. Ann Hematol [Internet]. 2021 Mar;100(3):645–51. 
• Ong SY, de Mel S, Grigoropoulos NF, Chen Y, Tan YC, Tan MSY, et al. High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. Blood Cancer J [Internet]. 2021 Aug 12;11(8):143.
• Lin G-W, Xu C, Chen K, Huang H-Q, Chen J, Song B, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2020 Feb;21(2):306–16.
• Ong SY, Phipps C, Nagarajan C, Tang T, Lim ST, Goh YT, et al. Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia. Vol. 61, Leukemia & lymphoma. United States; 2020. p. 225–7. 
• Ong SY, Phipps C, Kaur H, Tan L, Lee YS. Pralatrexate Induces Long-Term Remission in Relapsed Subcutaneous Panniculitis-Like T-Cell Lymphoma. Vol. 48, Annals of the Academy of Medicine, Singapore. Singapore; 2019. p. 298–300. 
• Ong SY, Ng HJ. Howell-Jolly bodies in systemic amyloidosis. Vol. 108, International journal of hematology. Japan; 2018. p. 119–20. 
• Ong SY, Li S-T, Wong GC, Ho AYL, Nagarajan C, Ngeow J. Delayed diagnosis of Shwachman diamond syndrome with short telomeres and a review of cases in Asia. Vol. 9, Leukemia research reports. 2018. p. 54–7. 
• Ong SY, Chin YA, Than H, Tan CW, Yap ES, Wong WH, et al. Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence. Ann Hematol. 2017;96(3):525–7. 
• Ong SY, Ho LP, Yeo PM, Ng HJ, Ang AL. Marked hypereosinophilia and rash as initial presentation of acute myeloid leukemia  with t(8;21). Vol. 106, International journal of hematology. Japan; 2017. p. 149–50. 
• Bari S, Seah KKH, Poon Z, Cheung AMS, Fan X, Ong S-Y, et al. Expansion and homing of umbilical cord blood hematopoietic stem and progenitor cells for clinical transplantation. Biol blood marrow Transplant J Am Soc Blood Marrow Transplant. 2015 Jun;21(6):1008–19. 
• Ong S-Y, Truong H-T-T, Diong CP, Linn Y-C, Ho AY-L, Goh Y-T, et al. Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation. BMC Hematol. 2015;15:8. 
• Ong S-Y, Ng HY, Surendran S, Linn YC, Chen Y, Goh YT, et al. Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma. Vol. 169, British journal of haematology. England; 2015. p. 754–6. 
• Fan X, Gay FPH, Ong S-Y, Ang JML, Chu PPY, Bari S, et al. Mesenchymal stromal cell supported umbilical cord blood ex vivo expansion enhances regulatory T cells and reduces graft versus host disease. Cytotherapy. 2013 May;15(5):610–9.